Bavarian Nordic Forecasted to Post Q1 2018 Earnings of ($0.25) Per Share (BVNRY)

Bavarian Nordic (OTCMKTS:BVNRY) – Investment analysts at Jefferies Group issued their Q1 2018 earnings per share (EPS) estimates for shares of Bavarian Nordic in a research note issued on Tuesday. Jefferies Group analyst P. Welford forecasts that the company will post earnings per share of ($0.25) for the quarter. Jefferies Group also issued estimates for Bavarian Nordic’s Q2 2018 earnings at ($0.23) EPS, Q3 2018 earnings at ($0.12) EPS, Q4 2018 earnings at ($0.05) EPS and FY2022 earnings at $0.01 EPS.

A number of other equities analysts also recently commented on the stock. Zacks Investment Research raised shares of Bavarian Nordic from a “sell” rating to a “hold” rating in a report on Monday, November 20th. ValuEngine downgraded shares of Bavarian Nordic from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd.

Bavarian Nordic (BVNRY) opened at $12.09 on Wednesday. The company has a market cap of $1,161.11, a PE ratio of 16.34 and a beta of -1.05. Bavarian Nordic has a 1-year low of $11.06 and a 1-year high of $22.70. The company has a current ratio of 10.27, a quick ratio of 9.89 and a debt-to-equity ratio of 0.01.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at

About Bavarian Nordic

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with's FREE daily email newsletter.

Leave a Reply